| ACTG 5217 FACT SHEET |
| The SETPOINT Study – A Randomized Study of the Effect of Immediate Treatment with Potent Antiretroviral Therapy versus Observation with Treatment as Indicated in Newly Infected HIV-1-Infected Subjects: Does Early Therapy Alter the Virologic Setpoint? |
Purpose of This Trial:
|
| To compare the safety and effectiveness of 36 weeks of treatment versus no treatment.
|
| Requirements to Enter Study: |
- Acquired HIV-1 infection within the past 6 months
- HIV viral load at least 500 copies/ml
- CD4 T cells at least 350 cells/mm3
- No prior HIV treatment
- No HIV progression to CDC category B or C disease
- No history of pancreatitis
|
| Study Design: |
|
Randomized (like flipping a coin) to either:
- Group A: Treatment with Emtricitabine/Tenofovir DF and Lopinavir/ritonavir (Kaletra) for 36 weeks (provided by study). If you are assigned to group A, you may also choose to take treatment other than Emtricitabine/Tenofovir DF, and Lopinavir/Ritonavir, but you would have to get these medications by prescriptions. These medications will not be provided by the study. After 36 weeks, participants will stop taking study medications.
or
- Group B: No treatment (observation) unless needed because HIV disease is progressing
At any time during the study, participants who are not on anti-HIV drugs may be encouraged to begin or restart based on symptoms or lab test results.
|
| Length of Study: |
| Up to 96 weeks
|
| Schedule of Study Appointments (about 1 hour each): |
|
Screening, pre-entry, entry and weeks 1, 2, 4, and then every 4 weeks. Visits include physical exams, blood draws, and questionnaires.
|
| Reimbursement: |
| Exams, lab tests, and study medications are provided at no cost. Participants will receive $20 per study visit.
|
| Contact: |
| Call 206-521-1978 and ask for Claire Stevens or Janine Maenza
|